Long-term Follow-up Study of BRL-101 for TDT

Launched by BIORAY LABORATORIES · Mar 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the long-term effects of a treatment called BRL-101 for people with transfusion-dependent beta-thalassemia, a type of blood disorder. The goal of the study is to observe how safe the treatment is over a long period and how well it works in improving the health of individuals who have already received BRL-101.

To participate in this trial, individuals must be between 3 and 35 years old and must have previously been treated with BRL-101 for their condition. There are no specific exclusion criteria, which means that most people who meet the age and treatment criteria can join. If you or a family member decides to participate, you can expect to be monitored closely for safety and effectiveness over time. This study is important because it aims to gather valuable information that could help future patients with similar health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
• • 2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
• Exclusion Criteria:
• • - There are no exclusion criteria for this study